This formulation enabled precise and tumor‐specific drug release, synergistically inhibiting both exosome biogenesis and PD‐L1 expression, reducing MDSC infiltration, and restoring CTL function.[349] Tregs suppress antitumor immune responses through molecules such as CTLA‐4 and IL‐10. The gene discussed is CTLA4; the disease is neoplasm.